Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Feb 23, 2024 10:53am
90 Views
Post# 35895560

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout) inthno .. No I am not saying what you are stating. And no I was not talking about the treatment of capital gains/losses as you would in your personal account. You don't seem to understand the principles of corporate tax transfers associated with corporate mergers and acquisitions. What I am talking about is the transfer of an acquired company's  accumulated deficit off of their balance sheet onto the balance sheet of the acquiring company's balance sheet. You can't seem to understand this corporate accounting feature. This transition is a net benefit to the acquiring company as it is "interpreted" as the acquiring company's  R&D expenses. Such a transaction appears as though the acquirer is significantly involved in research and development, when in fact the acquirer simply buys this "impression" when it acquirers another's assets and transfers the acquired company's balance sheet to its own. 
<< Previous
Bullboard Posts
Next >>